NASDAQ:CARA Cara Therapeutics (CARA) Stock Forecast, Price & News $3.26 -0.13 (-3.83%) (As of 05:34 PM ET) Add Compare Share Share Today's Range$3.26▼$3.3850-Day Range$3.09▼$4.9452-Week Range$2.94▼$12.98Volume1.09 million shsAverage Volume661,285 shsMarket Capitalization$175.94 millionP/E RatioN/ADividend YieldN/APrice Target$15.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Cara Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside385.7% Upside$15.83 Price TargetShort InterestBearish11.70% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews Sentiment-0.20Based on 2 Articles This WeekInsider TradingSelling Shares$42,624 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector477th out of 981 stocksPharmaceutical Preparations Industry225th out of 478 stocks 3.3 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.83, Cara Therapeutics has a forecasted upside of 385.7% from its current price of $3.26.Amount of Analyst CoverageCara Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.70% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 1.6 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.Search Interest16 people have searched for CARA on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,624.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions69.26% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.89) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cara Therapeutics (NASDAQ:CARA) StockCARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.Read More Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Stock News HeadlinesJune 6, 2023 | marketwatch.comSeveral Stocks Touch 52-Week Lows After S&P Indices MovesJune 3, 2023 | americanbankingnews.comBrokerages Set Cara Therapeutics, Inc. (NASDAQ:CARA) Target Price at $15.83June 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 29, 2023 | benzinga.comPain Relief Therapeutics Market to Grow Significantly by 2029- Brandessence Market ResearchMay 25, 2023 | fool.comCara Therapeutics (NASDAQ: CARA)May 25, 2023 | finance.yahoo.comCara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The MarkMay 21, 2023 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Downgraded to "Sell" at StockNews.comMay 20, 2023 | americanbankingnews.comCara Therapeutics, Inc. (NASDAQ:CARA) to Post Q2 2023 Earnings of ($0.60) Per Share, HC Wainwright ForecastsJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 19, 2023 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) PT Lowered to $15.00 at HC WainwrightMay 18, 2023 | msn.comUK drug pricing watchdog backs use of Cara, Vifor's Kapruvia in NHSMay 18, 2023 | finance.yahoo.comKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusMay 16, 2023 | msn.comB of A Securities Maintains Cara Therapeutics (CARA) Underperform RecommendationMay 16, 2023 | msn.comHC Wainwright & Co. Maintains Cara Therapeutics (CARA) Buy RecommendationMay 16, 2023 | finance.yahoo.comQ1 2023 Cara Therapeutics Inc Earnings CallMay 16, 2023 | msn.comCara Therapeutics Revenue Grows 29% To $6.2MMay 16, 2023 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Given New $4.00 Price Target at Bank of AmericaMay 15, 2023 | marketwatch.comCara Therapeutics Stock Up 6% on Narrower 1Q LossMay 15, 2023 | finance.yahoo.comCara Therapeutics Reports First Quarter 2023 Financial ResultsMay 15, 2023 | marketwatch.comStocks to Watch: Cara Therapeutics, Coherus BioSciences, Voxx InternationalMay 14, 2023 | americanbankingnews.comCara Therapeutics (CARA) to Release Earnings on MondayMay 11, 2023 | americanbankingnews.comCara Therapeutics, Inc. (NASDAQ:CARA) Receives $17.00 Average PT from BrokeragesMay 10, 2023 | americanbankingnews.comInsider Selling: Cara Therapeutics, Inc. (NASDAQ:CARA) CEO Sells 3,869 Shares of StockMay 4, 2023 | finance.yahoo.comCara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 65%May 1, 2023 | finance.yahoo.comCara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023April 19, 2023 | msn.comNeedham Reiterates Cara Therapeutics (CARA) Action List Buy RecommendationApril 19, 2023 | msn.comCannabis Stock Movers For April 18, 2023See More Headlines CARA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARA Company Calendar Last Earnings11/07/2021Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.83 High Stock Price Forecast$25.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+379.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-85,470,000.00 Net Margins-195.16% Pretax Margin-195.16% Return on Equity-49.31% Return on Assets-43.52% Debt Debt-to-Equity RatioN/A Current Ratio8.55 Quick Ratio8.34 Sales & Book Value Annual Sales$41.87 million Price / Sales4.25 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book1.12Miscellaneous Outstanding Shares53,970,000Free Float52,247,000Market Cap$178.10 million OptionableOptionable Beta0.87 Key ExecutivesChristopher A. PosnerPresident, Chief Executive Officer & DirectorRyan D. MaynardChief Financial OfficerFrèdèrique MenzaghiChief Scientific Officer, Senior VP-R&DJoana GoncalvesChief Medical OfficerScott M. TerrillionSecretary & Chief Compliance OfficerKey CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKAnnexonNASDAQ:ANNXXBiotechNASDAQ:XBITZevra TherapeuticsNASDAQ:ZVRAInflaRxNASDAQ:IFRXView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 8,491 shares on 5/22/2023Ownership: 0.452%JPMorgan Chase & Co.Bought 7,283 shares on 5/18/2023Ownership: 0.141%New York State Common Retirement FundSold 15,000 shares on 5/18/2023Ownership: 0.030%B. Riley Wealth Advisors Inc.Bought 2,500 shares on 5/17/2023Ownership: 0.090%Susquehanna International Group LLPSold 12,200 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CARA Stock - Frequently Asked Questions Should I buy or sell Cara Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARA shares. View CARA analyst ratings or view top-rated stocks. What is Cara Therapeutics' stock price forecast for 2023? 6 brokers have issued 12 month price objectives for Cara Therapeutics' shares. Their CARA share price forecasts range from $4.00 to $25.00. On average, they anticipate the company's stock price to reach $15.83 in the next year. This suggests a possible upside of 379.8% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts. How have CARA shares performed in 2023? Cara Therapeutics' stock was trading at $10.74 on January 1st, 2023. Since then, CARA stock has decreased by 69.3% and is now trading at $3.30. View the best growth stocks for 2023 here. When is Cara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CARA earnings forecast. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.34. The biopharmaceutical company had revenue of $20.27 million for the quarter, compared to analyst estimates of $15.74 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 49.31% and a negative net margin of 195.16%. During the same quarter in the previous year, the business earned ($0.35) EPS. What ETFs hold Cara Therapeutics' stock? ETFs with the largest weight of Cara Therapeutics (NASDAQ:CARA) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Pharmaceuticals ETF (XPH), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY). What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.09%), Bain Capital Life Sciences Investors LLC (4.08%), Farallon Capital Management LLC (3.70%), State Street Corp (3.53%), Kingdon Capital Management L.L.C. (2.28%) and Dimensional Fund Advisors LP (1.75%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $3.30. How much money does Cara Therapeutics make? Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $178.10 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510. This page (NASDAQ:CARA) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.